Development of a graphene oxide-poly lactide nanocomposite as a Smart Drug Delivery System

Ghamkhari, Aliyeh; Abbaspour‐Ravasjani, Soheil; Talebi, Mehdi; Hamishehkar, Hamed; Hamblin, Michael R.

doi:10.1016/j.ijbiomac.2020.12.084

Cited by 57 publications

(30 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table S1 reports the title, first author, journal, date of publication, and DOI for the seventeen publications [44,[64][65][66][67][68][69][70][71][72][73][74][75][76][77][78][79]. Those included were published in sixteen scientific journals ranging from 2008 to 2021.…”

Section: Methodsmentioning

confidence: 99%

“…Of these, 65% were published within the last five years (since 2016), highlighting the advancement of research and research interest in the area of graphene nanomaterials for drug delivery. Table S1 reports the title, first author, journal, date of publication, and DOI for the seventeen publications [43,[63][64][65][66][67][68][69][70][71][72][73][74][75][76][77][78]. Those included were published in sixteen scientific journals ranging from 2008 to 2021.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

2021

View full text Add to dashboard Cite

Cancer remains one of the leading causes of death worldwide despite extensive efforts at developing curative treatments. Chemotherapy, one of the most common forms of treatment, lacks specificity and can induce collateral damages to healthy surrounding tissues/cells and elicit off-target toxic side effects. The carbon-based nanomaterial graphene, can load aromatic drugs with high efficiency, has good biocompatibility, and can be easily functionalised with targeting ligands, antibodies, and biomolecules to increase the accuracy of targeting specific areas; graphene has therefore been explored as a nanocarrier for classical chemotherapy drugs. In this work, seventeen publications that report the release of doxorubicin (DOX) from 2D graphene-based nanohybrids (graphene oxide and reduced graphene oxide) for the treatment of breast and ovarian cancers have been identified based on a range of inclusion and exclusion criteria. To aid in the clinical translation of proof-of-concept studies, this work identifies the pre-clinical experimental protocols and analyses the release kinetics of these publications. Fifteen of the papers utilised a change in pH as the stimulus for drug release, and two utilised either near infrared (NIR) or ultrasound as the stimulus. The extracted drug release data from these publications were fit to four known kinetic models. It was found that the majority of these data best fit the Weibull kinetic model. The agreement between the kinetic data in previously published literature provides a predictable estimation of DOX release from graphene-based nanocarriers. This study demonstrates the potential conjugation of graphene and DOX in drug delivery applications, and this knowledge can help improve to the design and formulation of future graphene-based nanocarriers. In addition, the use of further experimental testing and the standardisation of experimental protocols will be beneficial for future work. The incorporation of computational modelling prior to pre-clinical testing will also aid in the development of controlled and sustained DOX release systems that offer efficient and efficacious results.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

2021

View full text Add to dashboard Cite

show abstract

“…Doxorubicin was loaded onto the prepared nanosystem with high loading capacity and efficiency (∼83%) could induce a higher apoptosis rate (∼12.27 %) of U251 cells compared with free doxorubicin (∼8.20 %). 103 Hamblin and co‐workers 104 have designed GO‐based polymeric nanocomposites (∼51 nm) for the delivery of doxorubicin against breast cancer; the drug release being 24.7% and 41.2% under neutral and acidic environments after 72 h. 104 To develop a dual‐drug loaded nanosystem for combinational cancer therapy, cisplatin and doxorubicin were loaded into a nanoplatform constructed from GO and PEG. 105 Consequently, the designed nanosystems could be efficiently delivered into tumor cells, introducing noticeable cell apoptosis and necrosis; these agents could inhibit the growth of tumor cells with enhanced efficacy, the rate of promoted apoptosis and necrosis effects on cancerous cells being ∼18.6%.…”

Section: G‐ and Go‐based Nanosystems For Cancer Therapymentioning

confidence: 99%

“…Doxorubicin was loaded onto the prepared nanosystem with high loading capacity and efficiency (∼83%) could induce a higher apoptosis rate (∼12.27 %) of U251 cells compared with free doxorubicin (∼8.20 %). 103 Hamblin and coworkers 104 have designed GO-based polymeric nanocomposites (∼51 nm) for the delivery of doxorubicin against breast cancer; the drug release being 24.7% and 41.2% under F I G U R E 2 Preparative process of multifunctional graphene oxide (GO)-based structures with pH-sensitive and controllable drug delivery properties. Reproduced with permission from Elsevier, 2016 100 neutral and acidic environments after 72 h. 104 To develop a dual-drug loaded nanosystem for combinational cancer therapy, cisplatin and doxorubicin were loaded into a nanoplatform constructed from GO and PEG.…”

Section: F I G U R Ementioning

confidence: 99%

Graphene and graphene oxide with anticancer applications: Challenges and future perspectives

Shafiee

Iravani

Varma

2022

MedComm

View full text Add to dashboard Cite

Graphene‐based materials have shown immense pertinence for sensing/imaging, gene/drug delivery, cancer therapy/diagnosis, and tissue engineering/regenerative medicine. Indeed, the large surface area, ease of functionalization, high drug loading capacity, and reactive oxygen species induction potentials have rendered graphene‐ (G‐) and graphene oxide (GO)‐based (nano)structures promising candidates for cancer therapy applications. Various techniques namely liquid‐phase exfoliation, Hummer's method, chemical vapor deposition, chemically reduced GO, mechanical cleavage of graphite, arc discharge of graphite, and thermal fusion have been deployed for the production of G‐based materials. Additionally, important criteria such as biocompatibility, bio‐toxicity, dispersibility, immunological compatibility, and inflammatory reactions of G‐based structures need to be systematically assessed for additional clinical and biomedical appliances. Furthermore, surface properties (e.g., lateral dimension, charge, corona influence, surface structure, and oxygen content), concentration, detection strategies, and cell types are vital for anticancer activities of these structures. Notably, the efficient accumulation of anticancer drugs in tumor targets/tissues, controlled cellular uptake properties, tumor‐targeted drug release behavior, and selective toxicity toward the cells are crucial criteria that need to be met for developing future anticancer G‐based nanosystems. Herein, important challenges and future perspectives of cancer therapy using G‐ and GO‐based nanosystems have been highlighted, and the recent advancements are deliberated.

show abstract

“…6,7 Therefore, it is urgent to establish a drug delivery system with hepatocellular carcinoma targeting and hypotoxicity for effective treatment of hepatocellular carcinoma. In recent years, nanomaterials have been widely used in new therapeutic modes for various diseases because of their good biocompatibility and high drug loading, for example, magnetic nanomaterials (Fe 3 O 4 ), [8][9][10][11] graphene oxide (GO), 12,13 inorganic nanomaterials (SiO 2 ) 14,15 etc. Among them, Fe 3 O 4 magnetic nanoparticles (MNPs) have excellent superparamagnetism, good biocompatibility, chemical stability, simple preparation as well as low price, and have attracted extensive research interest in drug delivery by nanocarriers.…”

Section: Introductionmentioning

confidence: 99%

Folic acid and deoxycholic acid derivative modified Fe₃O₄ nanoparticles for efficient pH-dependent drug release and multi-targeting against liver cancer cells

Wang

Wen

et al. 2021

RSC Adv.

View full text Add to dashboard Cite

show abstract

Development of a graphene oxide-poly lactide nanocomposite as a Smart Drug Delivery System

Cited by 57 publications

References 47 publications

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

Graphene and graphene oxide with anticancer applications: Challenges and future perspectives

Folic acid and deoxycholic acid derivative modified Fe₃O₄ nanoparticles for efficient pH-dependent drug release and multi-targeting against liver cancer cells

Contact Info

Product

Resources

About

Development of a graphene oxide-poly lactide nanocomposite as a Smart Drug Delivery System

Cited by 57 publications

References 47 publications

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

Drug Release Kinetics of DOX-Loaded Graphene-Based Nanocarriers for Ovarian and Breast Cancer Therapeutics

Graphene and graphene oxide with anticancer applications: Challenges and future perspectives

Folic acid and deoxycholic acid derivative modified Fe3O4 nanoparticles for efficient pH-dependent drug release and multi-targeting against liver cancer cells

Contact Info

Product

Resources

About

Folic acid and deoxycholic acid derivative modified Fe₃O₄ nanoparticles for efficient pH-dependent drug release and multi-targeting against liver cancer cells